March 28th, 2017
10:00 a.m. Pacific Daylight Time
1:00 p.m. Eastern Daylight Time
Accelerating the development of regenerative therapies: Large scale expansion of human mesenchymal stem cells
Pall has partnered with RoosterBio to commercialize Allegro™ Unison human mesenchymal stem cells (hMSCs) and bioprocess media to accelerate cell therapy and regenerative medicine development. Use of Allegro Unison products along with SoloHill microcarriers, Allegro biocontainers, and the PadReactor® bioreactor system moves the industry towards execution of the technology roadmap to achieve lot sizes of 100s of billions to >1 trillion hMSCs, without the need for extensive and costly process development. Large scale hMSC expansion is now rapidly achievable in a robust, scalable, reproducible, and economic manner.
This webinar details the total solution for large scale expansion of human mesenchymal stem cells. We will present a case study highlighting large scale cell culture and expansion of hMSCs to billions of cells, within ten days of culture, in a fed-batch 50L bioreactor system.
Register to Learn:
- How Allegro Unison hMSCs and bioprocess media, SoloHill microcarriers and Pall PadReactor systems enable large-scale hMSC expansion.
- Culture protocol for 200-fold hMSC expansion, within 10 days, in a single-use, fed-batch scalable manufacturing platform.
- How regenerative medicine and cell therapy developers can rapidly and economically move towards producing tens of billions to >1 trillion high quality hMSCs for product development programs in single-use bioreactors.
Senior Marketing Leader
Pall Life Sciences
(Westborough, MA, USA)
Tariq Haq is a Senior Marketing Leader in the Cell Culture Technologies marketing team at Pall Life Sciences. He has previously worked at GE Healthcare, Thermo Fisher Scientific, Millipore, and Becton Dickinson. Tariq holds degrees in Physics and Biotechnology from Aligarh Muslim University as well as in Biochemistry from Texas A&M University. He has extensive biotechnology experience and has authored scientific publications in peer-reviewed journals such as Science and Vaccine.
Jon Rowley, Ph.D.
Founder and Chief Technical Officer
RoosterBio Inc, Frederick, MD, USA
Jon A. Rowley, PhD, is the Founder and Chief Technical Officer of RoosterBio Inc and has a personal goal of making significant contributions to the commercial translation of living cellular technologies. Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 30 peer-reviewed manuscripts and 15 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy.
Mark Szczypka, Ph.D.
Senior Director, Applications & Product Development
Pall Life Sciences
(Ann Arbor, MI, USA)
Mark Szczypka is the Senior Director of Applications and New Product Development at Pall Life Sciences. Highly skilled in the field of cell culture applications, Mark previously held executive positions as President of SoloHill Engineering Inc., Director of Nephrology and Oncology at OncoImmune, and Senior Director Research and Development at RenaMed Biologics. With 15 years of experience in cell culture, he has numerous scientific publications. He holds a Ph. D. in Biological Chemistry from the University of Michigan. He was awarded a Howard Hughes Research Scientist fellowship for postdoctoral research during his tenure at the University of Washington, and his work in gene therapy was published in the Journal Neuron and was highlighted on World News tonight.